NCT06192849招募中2 期
A Phase II, Prospective, Multi-centre, Study to Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Juan LI, MD1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年12月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- DFS
研究概览
简要总结
This is a phase II, prospective, multi-centre study. To assess the efficacy and safety of furmonertinib in patients with epidermal growth factor receptor 20ins mutation positive stage IB-IIIA Non-small Cell Lung Carcinoma, following complete tumour resection with or without adjuvant chemotherapy.
The study plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
The primary endpoint is DFS. The secondary endpoint include DFS rate , OS and the change of HRQoL.
In addition, the peripheral blood ctDNA will be collected and analyzed in this study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide informed consent prior to any study specific procedures;
- •Male or female, aged at least 18 years;
- •Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for the tumor;
- •Patients must be classified post-operatively as Stage IB, II, or IIIA on the basis of pathologic criteria;
- •Complete recovery from surgery and standard post-operative therapy (if applicable);
- •Patient with EGFR 20 insertion mutation diagnosed histologically or cytologically, the reports must be issued or recognized by Tier 3A hospitals;
- •ECOG PS of 0 to 1;
- •For premenopausal women with childbearing potential, a pregnancy test must be performed within 14 days before the first dose, and the pregnancy test (blood or urine test) must be negative; female subjects must not be lactating;
排除标准
- •Patients who have had only segmentectomies or wedge resections;
- •Any prior anticancer therapy（excluding adjuvant platinum-based chemotherapy）;
- •Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4;
- •Treatment with an investigational drug within five half-lives of the compound or any of its related material;
- •History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for > 5 years following the end of treatment;
- •Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy;
- •Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV);
- •Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG Machine-derived QTc value;
- •Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG;
- •Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval;
- •Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD;
- •Inadequate bone marrow reserve or organ function;
研究组 & 干预措施
Furmonertinib
Experimental
This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
干预措施: Furmonertinib (Drug)
结局指标
主要结局
DFS
时间窗: From date of receiving therapy until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 4 years
Disease-free-survival
次要结局
- OS(From date of receiving therapy until date of death (by any cause in the absence of recurrence).Approximately 5 years following the first dose of study drugs)
- DFS rate(From date of receiving therapy until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 4 years. Assessed at 2,3,5 years.)
研究者
Juan LI, MD
Principal Investigator
Sichuan Cancer Hospital and Research Institute
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionNSCLCNCT05466149Allist Pharmaceuticals, Inc.100
进行中（未招募）
2 期
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06668961Sichuan Baili Pharmaceutical Co., Ltd.48
已完成
2 期
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MMMultiple MyelomaNCT01526694Azienda Ospedaliera di Bolzano30
已完成
2 期
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin SyndromeBCCs in Gorlin Syndrome PatientsNCT04893486Palvella Therapeutics, Inc.73
进行中（未招募）
2 期
First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerHER2-positive Gastric CancerNCT05586061Qilu Hospital of Shandong University55